Feb 23, 2021
Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference
Dec 07, 2020
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
Nov 17, 2020
Relmada Therapeutics to Participate in Upcoming Investor Conferences
Jul 13, 2020
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
Jun 23, 2020
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
May 27, 2020
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
Apr 28, 2020
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Mar 31, 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Mar 24, 2020
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Feb 25, 2020
Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
Jan 10, 2020
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
Dec 20, 2019
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Dec 09, 2019
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Dec 03, 2019
Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
Dec 03, 2019
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
Nov 19, 2019
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Oct 17, 2019
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
Oct 15, 2019
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Oct 14, 2019
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Oct 10, 2019
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market